Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy

Recent studies suggest that thiazolidinediones ameliorate diabetic nephropathy (DN) independently of their effect on hyperglycemia. In the current study, we confirm and extend these findings by showing that rosiglitazone treatment prevented the development of DN and reversed multiple markers of oxid...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Zhang, Hongyu, Saha, Jharna, Byun, Jaeman, Schin, MaryLee, Lorenz, Matthew, Kennedy, Robert T., Kretzler, Matthias, Feldman, Eva L., Pennathur, Subramaniam, Brosius, Frank C.
Format: Artigo
Jezik:Inglês
Izdano: American Physiological Society 2008
Teme:
Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2576144/
https://ncbi.nlm.nih.gov/pubmed/18667486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajprenal.90208.2008
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items